Traitement de l’hépatite chronique B

[1]  E. Schiff,et al.  A dose-ranging study of the efficacy and tolerability of entecavir in Lamivudine-refractory chronic hepatitis B patients. , 2005, Gastroenterology.

[2]  Thomas Berg,et al.  Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. , 2005, The New England journal of medicine.

[3]  Graeme Currie,et al.  Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. , 2005, The New England journal of medicine.

[4]  G. Gerken,et al.  Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial , 2005, The Lancet.

[5]  P. Marcellin,et al.  Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. , 2004, The New England journal of medicine.

[6]  D. Ganem,et al.  Hepatitis B virus infection--natural history and clinical consequences. , 2004, The New England journal of medicine.

[7]  M. Wulfsohn,et al.  Adefovir dipivoxil therapy for lamivudine‐resistant hepatitis B in pre– and post–liver transplantation patients , 2003, Hepatology.

[8]  Y. Chao,et al.  Peginterferon α‐2a (40 kDa): an advance in the treatment of hepatitis B e antigen‐positive chronic hepatitis B , 2003, Journal of viral hepatitis.

[9]  C. Gibbs,et al.  Hepatitis B virus genotypes and virologic response in 694 patients in phase III studies of adefovir dipivoxil , 2003 .

[10]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. , 2003, The New England journal of medicine.

[11]  M. Wulfsohn,et al.  Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. , 2003, The New England journal of medicine.

[12]  H. Van Vlierberghe,et al.  Entecavir is superior to lamivudine in reducing hepatitis B virus DNA in patients with chronic hepatitis B infection. , 2002, Gastroenterology.

[13]  A. Lok,et al.  HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. , 2002, Hepatology.

[14]  J. Cadranel.  Recommandations pour la pratique clinique pour la réalisation de la ponction biopsie hépatique. , 2002 .

[15]  M. Jonas,et al.  Clinical trial of lamivudine in children with chronic hepatitis B. , 2002, The New England journal of medicine.

[16]  N. Boyer,et al.  Traitement de l'hépatite C , 2002 .

[17]  M. Sherman,et al.  Safety and efficacy of oral entecavir given for 28 days in patients with chronic hepatitis B virus infection , 2001, Hepatology.

[18]  V. Calvez,et al.  Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study , 2001, The Lancet.

[19]  N. Leung,et al.  Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy , 2001, Hepatology.

[20]  F. Degos,et al.  Practices of Liver Biopsy in France: Results of a Prospective Nationwide Survey , 2000, Hepatology.

[21]  R. D. de Man,et al.  Acute Exacerbation of Chronic Hepatitis B Virus Infection After Withdrawal of Lamivudine Therapy , 2000, Hepatology.

[22]  P. Marcellin,et al.  [Pegylated interferon: new progress in treatment for chronic hepatitis C]. , 2000, Gastroenterologie clinique et biologique.

[23]  E. Schiff,et al.  Adefovir dipivoxil for the treatment of lamivudine‐resistant hepatitis B mutants , 2000, Hepatology.

[24]  J. Villeneuve,et al.  Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B , 2000, Hepatology.

[25]  E. Schiff,et al.  Lamivudine as initial treatment for chronic hepatitis B in the United States. , 1999, The New England journal of medicine.

[26]  P. Marcellin,et al.  Hepatitis C virus infection, alpha interferon therapy and thyroid dysfunction. , 1995, Journal of hepatology.

[27]  A. Detsky,et al.  Effect of Alpha-Interferon Treatment in Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B , 1993, Annals of Internal Medicine.

[28]  William M. Lee,et al.  Adefovir dipivoxil added to ongoing lamivudine in chronic hepatitis B with YMDD mutant hepatitis B virus. , 2004, Gastroenterology.

[29]  R. Rubin,et al.  Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. , 2004, Gastroenterology.

[30]  M. Brunetto,et al.  Treatment of HBeAg-negative chronic hepatitis B with interferon or pegylated interferon. , 2003, Journal of hepatology.

[31]  E. Schiff,et al.  Histological outcome during long-term lamivudine therapy. , 2003, Gastroenterology.

[32]  J. Sung,et al.  220 Effects of lamivudine on disease progression and development of liver cancer in advanced chronic hepatitis B: a prospective double-blind placebo-controlled clinical trial , 2003 .

[33]  F. Zoulim.  Hepatitis B virus resistance to antivirals: clinical implications and management. , 2003, Journal of hepatology.

[34]  A. Craxì,et al.  Interferon-α for HBeAg-positive chronic hepatitis B , 2003 .

[35]  H. Thomas,et al.  Mechanisms of action of interferon and nucleoside analogues. , 2003, Journal of hepatology.

[36]  E. Jury.  EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002 Geneva, Switzerland. Consensus statement (long version). , 2003 .

[37]  P. Marcellin,et al.  Tolerability of Treatments for Viral Hepatitis , 2001, Drug safety.